Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Samalizumab: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 460512243 of page Samalizumab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Bogalusa65 (talk | contribs) Referenced a clinical trial. |
||
| Line 1: | Line 1: | ||
{{Short description|Monoclonal antibody}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Samalizumab|oldid=460512243}} 460512243] of page [[Samalizumab]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 464386468 |
||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| Line 15: | Line 16: | ||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category= |
| pregnancy_category= |
||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
||
| Line 27: | Line 28: | ||
| excretion = |
| excretion = |
||
| CAS_number_Ref = {{cascite|changed|??}} |
| CAS_number_Ref = {{cascite|changed|??}} |
||
| CAS_number |
| CAS_number = 1073059-33-2 |
||
| UNII_Ref = {{fdacite|changed|FDA}} |
|||
| UNII = 64EUX713G6 |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| KEGG_Ref = {{keggcite|changed|kegg}} |
|||
| KEGG = D09961 |
|||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| C=6542 | H=10086 | N=1702 | O=2102 | S=46 |
| C=6542 | H=10086 | N=1702 | O=2102 | S=46 |
||
| molecular_weight = 147.7 kDa |
|||
}} |
}} |
||
'''Samalizumab''' is a humanized monoclonal antibody designed for oncology indications.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}}</ref> Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein [[CD200]]. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. <ref>{{cite web|title=Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200|publisher=[[J Immunother Cancer 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-]]|url=https://pubmed.ncbi.nlm.nih.gov/31443741/}}</ref> |
|||
Samalizumab was developed by [[Alexion Pharmaceuticals]]. |
|||
== References == |
|||
<references/> |
|||
{{monoclonals for immune system}} |
|||
[[Category:Monoclonal antibodies]] |
|||
{{monoclonal-antibody-stub}} |
|||
{{antineoplastic-drug-stub}} |
|||